- RecruitingPHASE3
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
This study compares two treatments for advanced left-sided bowel cancer that hasn't spread. It looks at how long people stay disease-free when given a new drug called amivantamab with chemotherapy, versus a standard drug called cetuximab with chemotherapy.
For: Colorectal NeoplasmsUnited States · Belgium · Brazil - RecruitingPHASE3
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
This study looks at a new drug, zolbetuximab, alongside usual treatments for stomach or gullet cancer that has spread or can't be removed. It aims to see if this combination helps people live longer by targeting specific proteins on cancer cells.
For: Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer · Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer · Metastatic Gastric Adenocarcinoma or CancerUnited States · Australia · Belgium - RecruitingPHASE2
A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer
This study is testing a new combination of medicines for advanced bowel cancer. It aims to see how safe and effective a new drug, telisotuzumab adizutecan, is when given with standard treatments. The study will look at side effects and whether the cancer activity changes.
For: Metastatic Colorectal CancerUnited States · Australia · Austria - AuthorisedTherapeutic confirmatory (Phase III)
A Randomized, Active-Controlled, Double-blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination with FOLFOX versus Bevacizumab in Combination with FOLFOX for the First-line Treatment of Metastatic Colorectal Cancer (HARMONi-GI3)
This study is looking at a new treatment called ivonescimab, given with standard chemotherapy (FOLFOX), for bowel cancer that has spread. We compare it to another treatment (bevacizumab) also with FOLFOX, to see which works best at stopping the cancer from growing.
For: Metastatic colorectal cancerBelgium · Italy · Spain - Active not recruitingPHASE3
Paediatric Hepatic International Tumour Trial
This study, called PHITT, is for children and young people up to 30 years old with liver cancers called hepatoblastoma (HB) and hepatocellular carcinoma (HCC). It aims to find better ways to treat these cancers by using tailored treatments and studying them closely.
For: Hepatoblastoma · Carcinoma, HepatocellularAustria · Belgium · Czechia - Active not recruitingPHASE3
A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
This study looks at a new drug, glofitamab, combined with standard chemotherapy (GemOx) for people with a type of blood cancer called diffuse large B-cell lymphoma (DLBCL) that has come back or not responded to previous treatments. It compares this new combination to a standard treatment.
For: Diffuse Large B-cell LymphomaUnited States · Australia · Belgium - Active not recruitingPHASE3
A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers
This study looks at a new drug, zanidatamab, combined with chemotherapy, and sometimes another drug called tislelizumab. It aims to see if this treatment works better and is safer than standard chemotherapy for advanced stomach and gullet cancers that have HER2.
For: Gastric Neoplasms · Gastroesophageal Adenocarcinoma · Esophageal AdenocarcinomaArgentina · Australia · Belgium - RecruitingPHASE2
A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
This study looks at new treatments for advanced stomach or gullet cancer. It combines a new drug, ABBV-400, with existing chemotherapy and another new drug, Budigalimab. We want to find the safest and most effective dose and see how well it works.
For: Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma · Gastroesophageal Junction Adenocarcinoma · Esophageal AdenocarcinomaUnited States · Belgium · Canada - Active not recruitingPHASE3
Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
This study looks at a new drug combination for adults with a type of blood cancer called diffuse large B-cell lymphoma (DLBCL) that has come back or hasn't responded to previous treatment. It compares the new drug with standard treatment to see if it works better.
For: Relapsed Diffuse Large B-Cell Lymphoma · Refractory Diffuse Large B-Cell LymphomaUnited States · Argentina · Belgium - RecruitingPHASE1
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
This study is for adults with advanced cancers in places like the lungs or stomach that are hard to treat or have spread. It's testing a new drug, PF-08046050, to see if it's safe and helps shrink these cancers, sometimes with other medicines.
For: Colorectal Neoplasms · Carcinoma, Non-Small-Cell Lung · Stomach NeoplasmsUnited States · Canada · China - RecruitingPHASE2, PHASE3
A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination With Fluorouracil, Folinic Acid, and Oxaliplatin (FOLFOX) Compared to Standard of Care in Adult Participants With First-Line Metastatic Pancreatic Ductal Adenocarcinoma
This study looks at a new drug, telisotuzumab adizutecan, combined with standard chemotherapy (FOLFOX) for advanced pancreatic cancer. It compares this combination to the usual treatment to see if it works better and is safe for adults.
For: Metastatic Pancreatic Ductal Adenocarcinoma · PDACUnited States · Australia · Israel - RecruitingPHASE2, PHASE3
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
This study is testing a new medicine, zilovertamab vedotin (ZV), combined with standard treatments for a type of lymphoma called diffuse large B-cell lymphoma (DLBCL). It's for people whose lymphoma has come back or hasn't responded to previous treatments.
For: DLBCL · Diffuse Large B-Cell LymphomaUnited States · Argentina · Australia - Active not recruitingPHASE3
A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-positive, HER2-negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (GLOW).
This study looks at a new drug, zolbetuximab, combined with chemotherapy for advanced stomach or food pipe cancer. It aims to see if this combination works better than chemotherapy alone for people with a specific protein in their cancer.
For: Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer · Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer · Metastatic Gastric Adenocarcinoma or CancerUnited States · Argentina · Canada - Active not recruitingPHASE3
A Study to Compare Zolbetuximab (IMAB362) and Chemotherapy With Placebo and Chemotherapy in Adults With Gastric Cancer.
This study looks at a new medicine called zolbetuximab, combined with chemotherapy, for adults with advanced stomach cancer. It aims to see if this combination works better than chemotherapy alone to stop the cancer from getting worse.
For: Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer · Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer · Metastatic Gastric Adenocarcinoma or CancerUnited States · Australia · Belgium - Active not recruitingPHASE3
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014)
This study tested new drug combinations for advanced oesophageal cancer. It looked at pembrolizumab with lenvatinib and chemotherapy, versus pembrolizumab and chemotherapy, to see which worked best and was safest. The study has now stopped, with no safety concerns being the reason.
For: Metastatic Esophageal Squamous Cell CarcinomaUnited States · Argentina · Canada - AuthorisedTherapeutic confirmatory (Phase III)
Efficacy of the use of neoadjuvant with/without hyperthermic intraperitoneal chemotherapy in the treatment of locally advanced colon cancer: A phase III multi-arm, randomized and controlled clinical trial (FOXHIPECT4)
This study is testing different ways to treat advanced colon or upper rectal cancer. It looks at adding a special heated chemotherapy wash to standard treatment during surgery to see if it helps people live longer without the cancer coming back. The aim is to find the best treatment.
Spain - Active not recruitingPHASE3
A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer
This study looks at new drug combinations for advanced bowel cancer that has spread and has a specific gene change (BRAF). It compares these new combinations with standard chemotherapy to see which works best for people who haven't had treatment for their spread cancer.
For: NeoplasmsUnited States · Argentina · Australia - RecruitingPHASE3
A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
This study looks at new drug combinations for stomach (gastric) or food pipe (GEJ) cancer that has a specific marker called HER2. It compares different treatment mixes to see which works best and is safest for advanced cancer.
For: HER2-positive Gastric Cancer · Gastroesophageal Junction AdenocarcinomaUnited States · Argentina · Australia - Active not recruitingPHASE3
Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)
This study looks at a new drug, pembrolizumab, for certain types of oesophageal cancer. It compares giving pembrolizumab alongside standard chemotherapy and radiotherapy with giving a dummy drug (placebo) with the same standard treatment. We want to see if the new drug can help people live longer or prevent the cancer from coming back.
For: Esophageal Squamous Cell Carcinoma (ESCC) · Gastroesophageal Junction Carcinoma (GEJC) · Esophageal Adenocarcinoma (EAC)United States · Argentina · Belgium - RecruitingPHASE2
Pan Tumor Rollover Study
This study looks at the long-term safety of different cancer treatments, including nivolumab, alone or combined with other medicines. It's for people with various types of cancer who are already receiving treatment in a related study, aiming to see how these treatments work over time.
For: CancerUnited States · Argentina · Australia - RecruitingPHASE3
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
This study is testing new combinations of medicines (sonesitatug vedotin, rilvegostomig, and capecitabine) for advanced stomach, gastroesophageal junction, or oesophageal cancers. It aims to see how well they work and if they are safe for people whose cancer has a specific marker called Claudin18.2.
For: Gastric Cancer · Gastroesophageal Junction Adenocarcinoma · Esophageal CancerUnited States · Australia · Austria - RecruitingPHASE2
A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies
This study is for cancer patients who are already taking part in another study using the drug adagrasib. It allows them to continue getting treatment if it's helping. It looks at how well adagrasib works long-term for various solid tumours, alone or with other cancer medicines.
For: Solid TumorsUnited States · Australia · Belgium - RecruitingPHASE3
A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
This study looks at a new way to give a cancer drug called tislelizumab for advanced stomach cancer. We're comparing injections under the skin to drips into a vein, alongside usual chemotherapy. We want to see if the injection works just as well and is easier for patients.
For: Metastatic Gastric Adenocarcinoma · Gastroesophageal Junction AdenocarcinomaUnited States · Argentina · Austria - Active not recruitingPHASE3
A Clinical Trial of a New Combination Treatment, Domvanalimab and Zimberelimab, Plus Chemotherapy, for People With an Upper Gastrointestinal Tract Cancer That Cannot be Removed With Surgery That Has Spread to Other Parts of the Body
This study is testing a new combination of medicines with chemotherapy for some upper gut cancers that have spread and can't be removed by surgery. It aims to see if the new combination works better than current treatments.
For: Advanced Upper Gastrointestinal Tract AdenocarcinomaUnited States · Argentina · Australia - RecruitingPHASE3
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
This study is testing if a new combination of medicines, including tucatinib, works better than current treatments for people with advanced HER2-positive bowel cancer. It also looks at side effects. Participants will be randomly assigned to receive either the new combination or standard care.
For: Colorectal NeoplasmsUnited States · Argentina · Australia - Active not recruitingPHASE3
Oxaliplatin, Leucovorin, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer
This study looks at treating stage 2 colon cancer after surgery. It compares standard chemotherapy with chemotherapy plus a drug called bevacizumab. The aim is to see if adding bevacizumab helps people stay cancer-free for longer.
For: Colon Adenocarcinoma · Stage IIA Colon Cancer AJCC v7 · Stage IIB Colon Cancer AJCC v7United States · Canada · Peru - RecruitingPHASE1
A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.
This study is testing a new medicine, PF-07799933, for advanced cancers with a specific gene change (BRAF alterations). It aims to see how safe and effective it is, sometimes combined with other medicines, for people when usual treatments haven't worked.
For: Melanoma · Non-Small-Cell Lung Cancer · Thyroid CancerUnited States · Canada · Israel - RecruitingPHASE2
A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma
This study looks at a new way to give a treatment called glofitamab, along with gemcitabine and oxaliplatin, for a type of blood cancer called B-cell non-Hodgkin's lymphoma. The goal is to make the treatment safer and easier to get, potentially as an outpatient.
For: B-Cell Non-Hodgkins LymphomaUnited States · Australia · Canada - RecruitingPHASE1, PHASE2
Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)
This study looks for new ways to treat advanced oesophageal cancer that has spread or can't be removed by surgery. It combines existing immunotherapy (pembrolizumab) with new experimental drugs, sometimes with chemotherapy. The main goal is to check safety and how well these treatments work.
For: Esophageal Squamous Cell CarcinomaUnited States · Brazil · Chile - RecruitingPHASE1, PHASE2
Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
This study looks at new drug combinations with a medicine called pembrolizumab and chemotherapy for advanced stomach or oesophageal cancer that can't be removed by surgery. It's in early stages (Phase 1/2) and aims to find safe doses and see how well the treatments work.
For: Gastroesophageal Junction · Gastroesophageal Adenocarcinoma · Esophageal NeoplasmsUnited States · Brazil · Chile - RecruitingPHASE3
A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)
This study looks at a new drug, calderasib, for advanced bowel cancer with a specific genetic change (KRAS G12C). Researchers want to see if adding calderasib to standard treatments helps people live longer without their cancer growing.
For: Colon Adenocarcinoma · Rectal AdenocarcinomaUnited States · Argentina · Australia - RecruitingPHASE1, PHASE2
A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer
This study is testing a new drug, amivantamab, for advanced bowel cancer. It checks how well it works alone or with standard chemotherapy, and how safe it is. The study aims to find better ways to treat advanced bowel cancer.
For: Advanced or Metastatic Colorectal CancerUnited States · Belgium · Canada - Active not recruitingPHASE2
Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors
This study is testing a new drug, futibatinib, alongside standard cancer treatments for people with advanced oesophageal or pancreatic cancer. We want to see if this new combination helps fight the cancer and how safe it is.
For: Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer · Esophageal Adenocarcinoma · Esophageal Squamous Cell CancerUnited States · France · Germany - RecruitingPHASE3
A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
This study looks at a new medicine called HLX22, combined with standard treatments, for people newly diagnosed with a certain type of stomach and food pipe cancer. It aims to see how well it works and if it's safe compared to current treatments.
For: Gastroesophageal-junction Cancer · Monoclonal Antibody · Gastric CancerUnited States · Argentina · Australia - Active not recruitingPHASE3
A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
This study looks at new treatments for Diffuse Large B-Cell Lymphoma (DLBCL) that has come back or not responded to previous treatment. It compares a new drug called epcoritamab with standard treatments to see which works best and is safest.
For: Diffuse Large B-Cell LymphomaUnited States · Argentina · Australia - Active not recruitingPHASE2, PHASE3
Circulating Tumor DNA Testing in Predicting Treatment for Patients With Stage IIA Colon Cancer After Surgery
This study looks at a blood test (ctDNA) for people with a certain stage of colon cancer after surgery. It helps doctors decide if chemotherapy is helpful by checking for tiny cancer cells left behind that regular scans can't see.
For: Colon Adenocarcinoma · Stage IIA Colon Cancer AJCC v8United States · Canada · Puerto Rico - RecruitingPHASE2
Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)
This study looks at new treatments for advanced stomach or oesophageal cancer with a specific protein called HER2. We're testing a new drug, trastuzumab deruxtecan, by itself or with other common cancer medicines to see if it's safe and effective.
For: Gastric CancerUnited States · Brazil · Canada - RecruitingPHASE1
A Study of ASP3082 in Adults With Advanced Solid Tumors
This study looks at a new drug, ASP3082, for adults with advanced solid cancers that have a specific genetic change called KRAS G12D. It checks how safe the drug is and what dose works best, sometimes with another drug called cetuximab.
For: Solid TumorUnited States · China · France - RecruitingPHASE2
A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer
This study looks at new drug combinations for advanced bowel cancer that hasn't spread widely. Researchers want to see if adding ONO-4578 and Opdivo® to standard treatment helps more than standard treatment alone. It's for people whose cancer creates a specific protein called PD-L1.
For: Colorectal CancerUnited States · Canada · France - Active not recruitingPHASE2
Radiation Therapy and Fluorouracil With or Without Combination Chemotherapy Followed by Surgery in Treating Patients With Stage II or Stage III Rectal Cancer
This study looks at different ways to combine radiation and chemotherapy before surgery for stage 2 or 3 bowel cancer. Doctors hope to shrink tumours, making surgery easier and more successful. It compares various treatment plans to see which works best.
For: Colorectal CancerUnited States · Canada - Active not recruitingPHASE3
A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)
This study looks at new drug combinations for advanced bowel cancer that has spread. It compares nivolumab alone, nivolumab with ipilimumab, and standard chemotherapy to see which works best for patients whose cancer has specific features (dMMR/MSI-H).
For: Metastatic Colorectal CancerUnited States · Argentina · Australia - Active not recruitingPHASE2
LEAn Body Mass Normalization of OXaliplatin Based Chemotherapy
This study is looking at a new way to give chemotherapy for Stage III colon cancer. Instead of adjusting the dose based on overall body size, it focuses on how much lean muscle a person has. The aim is to reduce side effects like nerve damage, which can be severe.
For: Stage III Colon CancerFrance - RecruitingPHASE1
A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001)
This study is testing a new drug called Calderasib, alone or with other treatments, for advanced cancers with a specific gene change (KRAS G12C). It's looking at how safe and effective these treatments are.
For: Advanced Solid TumorsUnited States · Argentina · Australia - Active not recruitingPHASE3
Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
This study is looking for a new treatment for pancreatic cancer that has spread. It compares a new medicine called RMC-6236 with standard chemotherapy for people whose cancer has already been treated once before. The aim is to see if the new medicine is safer and works better.
For: Pancreatic Cancer · PDAC · PDAC - Pancreatic Ductal AdenocarcinomaUnited States · France · Germany - Not yet recruitingPHASE3
Adjuvant Trial in Patients With Resected PDAC Randomized to Allocation of Oxaliplatin- or Gemcitabine-based Chemotherapy by Standard Clinical Criteria or by a Transcriptomic Treatment Specific Stratification Signature
This study looks at new ways to choose chemotherapy after pancreatic cancer surgery to prevent it from returning. Researchers are comparing standard methods with a new genetic test to see which works best for patients in the UK.
For: Pancreatic Ductal AdenocarcinomaGermany · Sweden - Active not recruitingPHASE2
Study of Atezolizumab + FLOT vs. FLOT Alone in Patients With GC/GEJ and High Immune Responsiveness
This study compares a new drug, atezolizumab, plus standard chemotherapy (FLOT) against FLOT alone for stomach or food pipe cancer. It focuses on patients whose cancer shows certain immune markers, aiming to see if the new combination is safer and more effective before and after surgery.
For: Gastric Cancer · Gastroesophageal Junction AdenocarcinomaGermany · Switzerland - RecruitingPHASE3
The Sagittarius Trial
This study looks at new ways to treat colon cancer after surgery to stop it coming back. It uses advanced tests called 'liquid biopsies' to help doctors choose the best treatment for each person, aiming for better results and fewer side effects.
For: Colon Cancer Stage II · Colon Cancer Stage IIIGermany · Italy · Spain - Active not recruitingPHASE1
ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer
This study is testing a new drug, ELVN-002, with existing treatments like trastuzumab and chemotherapy. It's for adults with certain advanced HER2-positive cancers, including breast, stomach, and bowel cancer. The main goal is to find a safe dose and see how well it works.
For: HER2-positive Breast Cancer · HER2-positive Gastric Cancer · HER2 Positive Solid TumorsUnited States · Belgium · France